COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
US speeds up B61-13 nuclear bomb production as programme moves further ahead of schedule
The US government plans to accelerate production even further after achieving key B61-13 milestones months ahead of schedule, as the programme advances amid growing US-China strategic competition.
-
Canada’s C$2 billion ACSV deal reinforces new defence industrial strategy as allies align
General Dynamics Land Systems-Canada is the country’s first strategic partner under the Defence Industrial Strategy’s Strategic Partnership Framework, an effort to provide companies with confidence to invest and boost the defence labour force.
-
New UK armed forces minister frames High North defence as vital to “homeland security”
The UK’s Minister for the Armed Forces Louise Sandher-Jones made her first appearance in the role before the House of Commons Defence Committee this week to highlight efforts to improve capability in the High North.
-
Canada seeks to strengthen industrial ties with the US on classified programmes
Ottawa explores expanding defence-industrial cooperation with Washington into sensitive programmes, an approach that could reshape NORAD modernisation, strengthen North American supply chains and create new opportunities for defence contractors.